Cite
MLA Citation
Camille Evrard et al.. “PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.” Digestive and liver disease, vol. 53, no. 4, 2021, pp. 420–426. http://access.bl.uk/ark:/81055/vdc_100127346899.0x000012